One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Efficacy of Concurrent Chemoradiotherapy With S-1 vs Radiotherapy Alone for Older Patients With Esophageal CancerA Multicenter Randomized Phase 3 Clinical Trial
Yongling Ji, MD1; Xianghui Du, MD1; Weiguo Zhu, MD2; et al Yanguang Yang, MD3; Jun Ma, MD4; Li Zhang, MD5; Jiancheng Li, MD6; Hua Tao, MD7; Jianhong Xia, MD8; Haihua Yang, MD9; Jin Huang, MD10; Yong Bao, MD11; Dexi Du, MD12; Degan Liu, MD13; Xiusheng Wang, MD14; Chaoming Li, MD15; Xinmei Yang, MD16; Ming Zeng, MD, PhD17; Zhigang Liu, MD18; Wen Zheng, MD19; Juan Pu, MD20; Jun Chen, MD21; Wangyuan Hu, MD22; Peijing Li, MD1; Jin Wang, MD1; Yujin Xu, MD1; Xiao Zheng, MD1; Jianxiang Chen, MS1; Wanwei Wang, MD2; Guangzhou Tao, MD2; Jing Cai, MD3; Jizhong Zhao, MD3; Jun Zhu, MD7; Ming Jiang, MD7; Yan Yan, MD8; Guoping Xu, MD10; Shanshan Bu, MD14; Binbin Song, MD16; Ke Xie, MD17; Shan Huang, MD17; Yuanda Zheng, BS1; Liming Sheng, MD1; Xiaojing Lai, MS1; Ying Chen, MD1; Lei Cheng, MS1; Xiao Hu, MD1; Wenhao Ji, MS1; Min Fang, MD1; Yue Kong, MS1; Xiaofu Yu, MS1; Huizhang Li, MS1; Runhua Li, MS1; Lei Shi, MD23; Wei Shen, MS23; Chaonan Zhu, MS23; Junwei Lv, MD23; Rong Huang, MD24; Han He, MD24; Ming Chen, MD1,25
Assessment of Prostate Cancer Treatment Among Black and White Patients During the COVID-19 Pandemic
Adrien N. Bernstein, MD1; Ruchika Talwar, MD2; Elizabeth Handorf, PhD3; et al Kaynaat Syed, MHA4; John Danella, MD5; Serge Ginzburg, MD6; Laurence Belkoff, DO7; Adam C. Reese, MD8; Jeffery Tomaszewski, MD9; Edouard Trabulsi, MD10; Eric A. Singer, MD, MA, MS11; Bruce Jacobs, MD12; Alexander Kutikov, MD1; Robert Uzzo, MD, MBA1; Jay D. Raman, MD13; Thomas Guzzo, MD, MPH2; Marc C. Smaldone, MD, MSHP1; Andres Correa, MD1
Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II)The Trans Tasman Radiation Oncology Group 13.01 Phase 2 Randomized Clinical Trial
Shankar Siva, PhD1,2; Mathias Bressel, MSc3; Tao Mai, PhD4; et al Hien Le, MBBS5; Shalini Vinod, MD6; Harini de Silva, PhD7; Sean Macdonald, BSc (Hons)7; Marketa Skala, MBBS8; Nicholas Hardcastle, PhD9; Angela Rezo, MBBS10; David Pryor, MBBS4; Suki Gill, MBBS11; Braden Higgs, MBBS5; Kassandra Wagenfuehr, BSc12; Rebecca Montgomery, BBiomedSc12; Raef Awad, MD8; Brent Chesson, BAppSci (Hons)13; Thomas Eade, MBChB14; Wenchang Wong, MBBS15; Giuseppe Sasso, MBChB16; Richard De Abreu Lourenco, PhD17; Tomas Kron, PhD2,4; David Ball, MD1,2; Paul Neeson, PhD2,7; for the Stereotactic Ablative Fractionated Radiotherapy Versus Radiosurgery for Oligometastatic Neoplasia to the Lung (SAFRON) II Study Investigators
Effects of Exercise on Cardiorespiratory Fitness and Biochemical Progression in Men With Localized Prostate Cancer Under Active SurveillanceThe ERASE Randomized Clinical Trial
Dong-Woo Kang, PhD1,2; Adrian S. Fairey, MD3; Normand G. Boulé, PhD1; et al Catherine J. Field, PhD4; Stephanie A. Wharton, BSc1; Kerry S. Courneya, PhD1
Accelerated Hypofractionated Image-Guided vs Conventional Radiotherapy for Patients With Stage II/III Non–Small Cell Lung Cancer and Poor Performance StatusA Randomized Clinical Trial
Puneeth Iyengar, MD, PhD1,2,3; Elizabeth Zhang-Velten, MD, PhD1,2,3; Laurence Court, PhD4; et al Kenneth Westover, MD, PhD1,2,3; Yulong Yan, PhD1,2,3; Mu-Han Lin, PhD1,2,3; Zhenyu Xiong, PhD1,2,3; Mehul Patel, MD5; Douglas Rivera, MD6; Joe Chang, MD, PhD4; Mark Saunders, MD7; Anand Shivnani, MD8; Andrew Lee, MD9; Randall Hughes, MD1,2,3; David Gerber, MD1,2,3; Jonathan Dowell, MD1,2,3; Ang Gao, MS1,2,3; John Heinzerling, MD10; Ying Li, MD11; Chul Ahn, PhD1,2,3; Hak Choy, MD1,2,3; Robert Timmerman, MD1,2,3
Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer
Tal Goshen-Lago, PhD1; Ithai Waldhorn, MD1; Roy Holland, MD1; et al Moran Szwarcwort-Cohen, PhD2; Anat Reiner-Benaim, PhD3; Yael Shachor-Meyouhas, MD4,5; Khetam Hussein, MD4,5; Liana Fahoum, MSc1; Mali Baruch, BSc1; Avivit Peer, MD1; Yoram Reiter, PhD6; Ronit Almog, MD3; Michael Halberthal, MD4,5; Irit Ben-Aharon, MD, PhD1,5,6
Human Papillomavirus Persistence and Association With Recurrent Cervical Intraepithelial Neoplasia After Cryotherapy vs Loop Electrosurgical Excision Procedure Among HIV-Positive WomenA Secondary Analysis of a Randomized Clinical Trial
Michael H. Chung, MD, MPH1,2,3; Hugo De Vuyst, MD, PhD4; Sharon A. Greene, PhD, MPH2; et al Nelly R. Mugo, MBChB, MMed2,5; Troy D. Querec, PhD6; Evans Nyongesa-Malava, MBChB7; Anthony Cagle, PhD2; Samah R. Sakr, MBChB7; Stanley Luchters, MD, MPH, PhD3,8; Marleen Temmerman, MD, MPH, PhD3,9; Elizabeth R. Unger, MD, PhD6; Christine J. McGrath, PhD, MPH2
Association of Combined Focal 22q11.22 Deletion and IKZF1 Alterations With Outcomes in Childhood Acute Lymphoblastic Leukemia
David Spencer Mangum, MD1; Julia A. Meyer, PhD2,3; Clinton C. Mason, PhD2; et al Soheil Shams, PhD4; Luke D. Maese, DO2; Jamie D. Gardiner, PhD5; Jonathan M. Downie, MD, PhD6; Deqing Pei, MS7; Cheng Cheng, PhD7; Adam Gleason, MS8; Minjie Luo, PhD8; Ching-Hon Pui, MD9; Richard Aplenc, MD, PhD10; Stephen P. Hunger, MD10; Mignon Loh, MD3; Mel Greaves, PhD11; Nikolaus Trede, MD, PhD12; Elizabeth Raetz, MD13; J. Kimble Frazer, MD, PhD14; Charles G. Mullighan, MD15; Michael E. Engel, MD, PhD16; Rodney R. Miles, MD, PhD17; Karen R. Rabin, MD, PhD18; Joshua D. Schiffman, MD2,5,19
Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal CancerThe Phase 2 Single-Arm Clinical CAVE Trial
Erika Martinelli, MD, PhD1; Giulia Martini, MD, PhD1; Vincenzo Famiglietti, PhD1; et al Teresa Troiani, MD, PhD1; Stefania Napolitano, MD, PhD1; Filippo Pietrantonio, MD, PhD2; Davide Ciardiello, MD1; Marinella Terminiello, MD1; Carola Borrelli, MD1; Pietro Paolo Vitiello, MD1; Filippo De Braud, MD, PhD2; Federica Morano, MD2; Antonio Avallone, MD3; Nicola Normanno, MD, PhD4; Anna Nappi, MD3; Evaristo Maiello, MD5; Tiziana Latiano, MD5; Alfredo Falcone, MD6; Chiara Cremolini, MD6; Daniele Rossini, MD6; Giuseppe Santabarbara, MD7; Carmine Pinto, MD8; Daniele Santini, MD, PhD9; Claudia Cardone, MD1,3; Nicoletta Zanaletti, MD1,3; Alessandra Di Liello1; Daniela Renato1; Lucia Esposito1; Francesca Marrone, BS1; Fortunato Ciardiello, MD, PhD1,5
Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial CarcinomaA Phase 2 Randomized Clinical Trial
Sumanta K. Pal, MD1; Paul H. Frankel, PhD1; Amir Mortazavi, MD2; et al Matthew Milowsky, MD3; Ulka Vaishampayan, MD4; Mamta Parikh, MD5; Yung Lyou, MD1; Peng Weng, MD6; Rahul Parikh, MD7; Benjamin Teply, MD8; Robert Dreicer, MD9; Hamid Emamekhoo, MD10; Dror Michaelson, MD11; Christopher Hoimes, MD12; Tian Zhang, MD12; Sandy Srinivas, MD13; William Y. Kim, MD3; Yujie Cui, MS1; Edward Newman, MD1; Primo N. Lara Jr, MD5
Projected Association of Human Papillomavirus Vaccination With Oropharynx Cancer Incidence in the US, 2020-2045
Yuehan Zhang, ScM1; Carole Fakhry, MD1,2; Gypsyamber D’Souza, PhD1
Effectiveness of Adding Everolimus to the First-line Treatment of Advanced Breast Cancer in Premenopausal Women Who Experienced Disease Progression While Receiving Selective Estrogen Receptor ModulatorsA Phase 2 Randomized Clinical Trial
Ying Fan, MD1; Tao Sun, MD2; Zhimin Shao, MD3; et al Qingyuan Zhang, MD4; Quchang Ouyang, MD5; Zhongsheng Tong, MD6; Shusen Wang, MD7; Yang Luo, MD1; Yuee Teng, MD8; Xiaojia Wang, MD9; Shu Wang, MD10; Qiang Liu, MD11; Jifeng Feng, MD12; Kunwei Shen, MD13; Yanqiu Song, MD14; Jiayu Wang, MD1; Fei Ma, MD1; Qing Li, MD1; Pin Zhang, MD1; Binghe Xu, MD, PhD1
Cardioprotective Strategy for Patients With Nonmetastatic Breast Cancer Who Are Receiving an Anthracycline-Based ChemotherapyA Randomized Clinical Trial
Lorenzo Livi, MD1,2; Giuseppe Barletta, MD3; Francesca Martella, MD4; et al Calogero Saieva, MD5; Isacco Desideri, MD1,2; Carlotta Bacci, MD4; Maria Riccarda Del Bene, MD3; Mario Airoldi, MD6; Domenico Amoroso, MD7; Luigi Coltelli, MD8; Vieri Scotti, MD1,2; Carlotta Becherini, MD1,2; Luca Visani, MD1,2; Viola Salvestrini, MD1,2; Matteo Mariotti1,2; Fulvia Pedani, MD6; Marco Bernini, MD, PhD9; Luis Sanchez, MD9; Lorenzo Orzalesi, MD9; Jacopo Nori, MD10; Simonetta Bianchi, MD11; Iacopo Olivotto, MD, PhD12; Icro Meattini, MD1,2
The Inclusion of Women in Global Oncology Drug Trials Over the Past 20 Years
Kristina Jenei, BSN, MSc1; Daniel E. Meyers, MD, MSc2; Vinay Prasad, MD, MPH3
Use of an Analytics and Electronic Health Record–Based Approach for Targeted COVID-19 Vaccine Outreach to Marginalized Populations
Jacob Stein, MD, MPH1,2; Megan Fasold, BSN, MBA1,3; Karyn Jean Daguerre, BSN, MPH, OCN1,3; et al Jaime Richardson, BSN, OCN, CCRP1,3; Summer Cheek, BSN, OCN1,3; Marjory Charlot, MD, MPH, MSc1,2; Ethan Basch, MD, MSc1,2,4
Recommendations for Age-Appropriate Testing, Timing, and Frequency of Audiologic Monitoring During Childhood Cancer TreatmentAn International Society of Paediatric Oncology Supportive Care Consensus Report
Annelot J. M. Meijer, MSc1; Marry M. van den Heuvel-Eibrink, MD, PhD1,2; Beth Brooks, MSc3,4; et al Antoinette G. am Zehnhoff-Dinnesen, MD, PhD5; Kristin R. Knight, MSc6; David R. Freyer, DO, MSc7,8,9,10; Kay W. Chang, MD11; Barbara Hero, MD, PhD12; Vassilios Papadakis, MD, PhD13; A. Lindsay Frazier, MD, PhD14; Claudia Blattmann, MD, PhD15; Rachael Windsor, MD, PhD16; Bruce Morland, MD, PhD17; Eric Bouffet, MD, PhD18; Stefan Rutkowski, MD, PhD19; Godelieve A. M. Tytgat, MD, PhD1; James I. Geller, MD20; Lisa L. Hunter, PhD21; Lillian Sung, MD, PhD18,22; Gabriele Calaminus, MD, PhD23; Bruce C. Carleton, PharmD24,25,26; Hiske W. Helleman, PhD27; Jennifer H. Foster, MD, PhD28; Mariana Kruger, MD, PhD29; Richard J. Cohn, MD, PhD30,31; Wendy Landier, MD, PhD32; Martine van Grotel, MD, PhD1; Penelope R. Brock, MD, PhD33; Alexander E. Hoetink, PhD27; Kaukab M. Rajput, PhD34; for the Society of Paediatric Oncology Supportive Care Committee
Application of Information Technology to Clinical Trial Evaluation and EnrollmentA Review
Mitchell S. von Itzstein, MD1,2; Melanie Hullings, BSE2; Helen Mayo, MLS3; et al M. Shaalan Beg, MD1,2; Erin L. Williams, MBA2; David E. Gerber, MD1,2,4
Anuric Kidney Failure in a Patient With Metastatic Melanoma
Avani M. Kolla, BPhil1; George Jour, MD1; Janice M. Mehnert, MD2
Promoting Inclusion of Members of Racial and Ethnic Minority Groups in Cancer Drug Development
Lola Fashoyin-Aje, MD, MPH1; Julia A. Beaver, MD1; Richard Pazdur, MD1
Clinical Trial Enrollment of Racial, Ethnic, and Underrepresented Groups—Leveraging a Digital Infrastructure
Matthew Culbert, MD1; Oluwadamilola T. Oladeru, MD, MA1
Treatment Options for Relapsed and Refractory Multiple MyelomaA Luxury or a Challenge?
Samer Al Hadidi, MD, MS1,2; Sarvari Yellapragada, MD3
Primary Chemoradiotherapy for Older Patients With Esophageal Cancer
Jennifer R. Eads, MD1; Daniel G. Haller, MD1
The Intersection of Societal Inequalities and Health CareLessons Learned From the COVID-19 Pandemic
Randy Vince Jr, MD, MS1
Managing Pulmonary Oligometastatic Disease With Stereotactic Body Radiation Therapy—Moving the Field Forward 1 Organ at a Time
Arya Amini, MD1
The Power of Exercise to Influence Cardiovascular and Oncologic Outcomes—Survival of the Fittest
Neha Vapiwala, MD1
Radiation Dose and Fractionation in Locally Advanced Lung CancerA Simple Question With a Complicated Answer
Melin J. Khandekar, MD, PhD1; Florence K. Keane, MD1
Single-Dose Radiotherapy for Prostate Cancer—Lessons Learned From Single-Fraction High-Dose-Rate Brachytherapy
Bryan S. Squires, MD1; Daniel J. Krauss, MD1
Single-Dose Radiotherapy for Prostate Cancer—Lessons Learned From Single-Fraction High-Dose-Rate Brachytherapy—Reply
Carlo Greco, MD1; Zvi Fuks, MD1,2
Association of Adjuvant Immunotherapy Duration With Chronic Immune-Related Adverse Events
Elie Rassy, MD, MSc, MPH1; Barbara Pistilli, MD1; Caroline Robert, MD, PhD1
Association of Adjuvant Immunotherapy Duration With Chronic Immune-Related Adverse Events—Reply
Douglas B. Johnson, MD, MSCI1; J. Randall Patrinely Jr, MD, MBA2; Fei Ye, PhD3
Population-Based Prostate Cancer Screening With Magnetic Resonance Imaging or Ultrasonography—The IP1-PROSTAGRAM Study
Zhu Oong, MBChB, MRCP1; Omi Parikh, BSc (Hons), MBChB (Hons), MRCP1
Population-Based Prostate Cancer Screening With Magnetic Resonance Imaging or Ultrasonography—The IP1-PROSTAGRAM Study—Reply
David Eldred-Evans, MBBS, MRCS1; Hashim U. Ahmed, PhD, BM, BCh, MA1
Errors in Reported Primary and Secondary Outcomes and Table Numbers in a Trial of Radiotherapy for Pain Relief in Patients With Bone Metastases
Quynh-Nhu Nguyen, MD1
Randomized Clinical Trials in the Era of Precision Oncology—The Role of End Points, Industry Funding, and Medical Writing Integrity
Alessandro Rizzo, MD1; Veronica Mollica1; Francesco Massari, MD1
Randomized Clinical Trials in the Era of Precision Oncology—The Role of End Points, Industry Funding, and Medical Writing Integrity
David J. Stewart, MD1; Paul Wheatley-Price, MD1
Randomized Clinical Trials in the Era of Precision Oncology—The Role of End Points, Industry Funding, and Medical Writing Integrity
Thomas M. Schindler, PhD1,2; Jacqueline M. Marchington, PhD, CMPP3,4; Gail V. Flores, PhD5,6
Randomized Clinical Trials in the Era of Precision Oncology—The Role of End Points, Industry Funding, and Medical Writing Integrity—Reply
Joseph C. Del Paggio, MD1; Elizabeth A. Eisenhauer, MD2; Christopher M. Booth, MD2,3
Immunochemotherapy as First-line Treatment for Locally Advanced or Metastatic Squamous Non–Small Cell Lung Cancers
Shujie Huang, MD1,2; Zhen Gao, MD1,3; Guibin Qiao, MD, PhD1,2,3
Immunochemotherapy as First-line Treatment for Locally Advanced or Metastatic Squamous Non–Small Cell Lung Cancers—Reply
Jie Wang, MD, PhD1; Shiang Jiin Leaw, MD2; Shun Lu, MD, PhD3
